Insights of biosimilars through SWOT analysis

Expert Opinion on Biological Therapy

Volumn 14, Issue 2, 2014, Pages 139-144

  Patel, Mayur Mahendrakumar ^a   Shah, Pranali Jatin ^a   Patel, Bhoomika Mayur ^a  

^a NIRMA UNIVERSITY   (India)

Author keywords

Biobetters; Biopharmaceuticals; Biosimilar; SWOT analysis

Indexed keywords

BIOBETTER AGENT; BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; MOLECULE TRANSPORT AGENT; SMALL MOLECULE DRUG; UNCLASSIFIED DRUG;

CHEMICAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG PURIFICATION; IMMUNOGENICITY; MOLECULAR SIZE; MOLECULAR WEIGHT; PATENT; PROTEIN GLYCOSYLATION; PROTEIN STRUCTURE; REVIEW;

BIOSIMILAR PHARMACEUTICALS; CANADA; DRUG AND NARCOTIC CONTROL; DRUG DESIGN; DRUG INDUSTRY; DRUG LABELING; DRUGS, GENERIC; FORECASTING; REPUBLIC OF KOREA; THERAPEUTIC EQUIVALENCY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84891944918     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2014.849689     Document Type: Review

References (15)

1. Woodcock J, Griffin J, Behrman R, et al. The FDA's assessment of follow on protein products: a historical perspective. Nat Rev Drug Discov 2007;6:437-42
2. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol 2008;19:411-19
3. Dranitsaris G, Amir E, Dorward K. Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations. Drugs 2011;71:1-10
4. Karpusas M, Whitty A, Runkel L, et al. The structure of human interferon-beta: implications for activity. Cell Mol Life Sci 1998;54:1203-16
5. Nowicki M. Basic facts about biosimilars. Kidney Blood Press Res 2007;30:267-72
6. Kling J. Fresh from the biologic pipeline-2010. Nat Biotechnol 2011;29:197-200
7. Available from: http://www.statista.com/statistics/241962/top-producers- of-biopharmaceuticals-based-on-revenue-2011/[Accessed on 7 June 2013]
8. Available from: http://www.stellarix.com/blog/review-on-the-current-and- future-trends-of-biosimilar-market-in-usa-and-india/[Accessed on 7 June 2013]
9. Sekhon BS, Saluja V. Biosimilars: an overview. Biosimilars 2011;2011:1-11
10. Marshall SA, Lazar GA, Chirino AJ, et al. Rational design and engineering of therapeutic proteins. Drug Discov Today 2003;8:212-21
11. Beck A. European medicines agency workshop on biosimilars monoclonal antibodies: perspective from the EU. MAbs 2009;1:406-10
12. Schellekens H. Follow-on biologics: challenges of the 'next generation'. Nephrol Dial Transplant 2005;20:iv31-6
13. Available from: http://www.gabionline. net/Biosimilars/Research/ Biosimilars-or-biobetters-what-does-the-future-hold/% 28highlight%29/ %20Biosimilars%20or% 20biobetters%E2%80%93what%20does%20the%20future%20hold [Accessed on 7 June 2013]
14. Dinwoodie N. Biobetters and the Future Biologics Market. BioPharm International 2011;24:31-5
15. Casadevall N, Rossert J. Importance of biologic follow-ons: experience with EPO. Best Pract Res Clin Haematol 2005;18:381-7